Moreover, sunitinib in combination with the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody shows a synergistic antitumor effect by promoting tumor-infiltrating lymphocyte activity in melanoma and NSCLC mouse models (Li H. et al., 2020). This evidence concerns the gene CTLA4 and melanoma.